Investment Opportunity

AngioSoma (OTCBB: SOAN) prides itself on our technology, patents, team and potential medical breakthroughs. Below please find our May 2021 Investment Slide Deck for review.
Please contact investorrelations@angiosoma.com with any questions.
Thank you.

INFORMATION SOURCES

AngioSoma, Inc. is a publicly traded clinical stage biotechnology company with the OTCBB ticker symbol SOAN. The company has a patented formulation of currently available drugs which have been shown, in our formulation, to enhance the quality of life for Multiple Sclerosis patients.

AngioSoma does not provide forward-looking information and will consistently update our website as appropriate. If you would like to reach out to our investor relations department, please contact us below or email investorrelations@angiosoma.com

Investor Relations Contact

Professionals

Transfer Agent
Standard Registrar and Transfer Company
440 East 400 South, Suite 200
Salt Lake City, UT 84111
Phone: 801-571-8844 or 801-596-2150
Legal Counsel
Sonfield & Sonfield, Attorneys at Law (information on OTC Markets)
2500 Wilcrest Drive, Suite 300, Houston, TX 77042
Accountants
M&K CPAS, PLLC (information on OTC Markets)
4100 North Sam Houston Pkwy W, Suite 200-B, Houston, TX 77086
(832) 242-9950